- Outlook 2021: Adjusted EBITDA of €2.1 billion to €2.3 billion
- Sales rise 4 percent in first quarter, adjusted EBITDA gains 15 percent
- Free cash flow almost triples to €312 million
Essen, Germany. Evonik is more positive about its earnings for the year as a whole after posting a strong first quarter. Higher demand worldwide and improved selling prices in the quarter led to an increase in sales and earnings. The three growth divisions – Specialty Additives, Nutrition & Care and Smart Materials - were the main driver, showing significant growth.
For 2021, Evonik now expects adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) of between €2.1 billion and €2.3 billion. Previously the bottom end of the forecast range was €2.0 billion. The outlook for sales remains at €12 billion to €14 billion for the year. In 2020 Evonik posted adjusted EBITDA of €1.91 billion and sales of €12.2 billion.
In the first quarter adjusted EBITDA gained 15 percent to €588 million compared with the same quarter in 2020. Compared with the first quarter of 2019 the gain was 9 percent.
Sales rose 4 percent to €3.36 billion in the first three months compared with the first quarter in the previous year. Adjusted net income increased 32 percent to €239 million.
Free cash flow almost tripled in the quarter to €312 million, boosted by the improved business performance, strict management of net working capital and lower tax payments. Free cash flow was also higher than the pre-pandemic level of €159 million in the first quarter of 2019.
Development of the divisions
The division's sales rose 6 percent to €907 million in the first quarter. Additives for the coatings industry were in much greater demand in all regions with sales in this area growing considerably. An increase in demand for durable goods boosted sales of additives for polyurethane foams for products such as mattresses or refrigerators. Demand for additives for the construction industry remained robust. Renewable energy products saw significantly more demand, especially in Asia. Adjusted EBITDA increased by 14 percent to €273 million.
Nutrition & Care
Sales at Nutrition & Care rose 4 percent to €780 million in the first quarter. Sales of essential amino acids remained stable. Products for the health and care sector benefited from good demand. In particular, active ingredients for cosmetic applications showed a continued positive development. Adjusted EBITDA improved by 21 percent to €143 million thanks to higher selling prices and active cost management.
The division's sales improved by 6 percent to €909 million in the first quarter. In the area of inorganic products, the tire silica business benefited from a global economic upturn. Demand for products from the hygiene and care sectors as well as for environmental applications remained robust. The catalyst business benefited from the inclusion of Porocel, which was acquired in November 2020. High-performance polymers saw good demand from the automotive industry. Sales of polyamide 12 powder also increased. Adjusted EBITDA rose 4 percent to €173 million at the division.
The division's sales fell by 1 percent to €580 million in the first quarter. Sales of C4 products rose as demand increased and selling prices climbed. The business development of the superabsorbents was affected by lower production output as a result of severe weather. Adjusted EBITDA rose from €18 million to €42 million.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.Asia Pacific is a strong driving force of the global economy and an important source of innovation. Consequently Evonik endeavors to further grow its business in the region. Sales reached €2.84 billion in 2020 and the company employs over 5,000 people at more than 50 production sites in Asia Pacific. In Taiwan, we now employ over 200 employees which including 1 office based in Taipei and 1 production site based in Taoyuan.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.